Topic Path
TB-500 & Thymosin Beta-4
TB-500 and thymosin beta-4 — the naming confusion untangled, what SGV's teachers claim for tissue repair, and the compound's regulatory status.
TB-500 and thymosin beta-4 — the naming confusion untangled, what SGV’s teachers claim for tissue repair, and the compound’s regulatory status.
This hub is part of the SGV peptide library — start at the Peptides topic hub for the full map. Everything below is a roundup of what the teachers in this library say in their own videos, attributed to them. SGV draws no medical conclusions, and nothing here is dosing or sourcing guidance.
First, the naming confusion
The single most useful episode in this corner of the library is Nathalie Niddam’s TB500 vs Thymosin Beta 4, with CanLab founder Jean-François Tremblay. Tremblay explains that TB-500 is a short fragment of the much longer thymosin beta-4 protein, and that different fragments of the parent molecule are associated in his account with different activities, from tissue repair to anti-fibrotic effects. He argues the full-length molecule offers broader actions, including on nerves and immune regulation, while the fragment is narrower and more cost-efficient for targeted musculoskeletal repair. The conversation also widens into how peptide fragments get isolated and marketed, and how to read research critically — since, as they note, abstracts can oversell narrow, early findings. Note, as the episode flags, that the guest founded a peptide company.
Where it shows up in the library
Dr. Andrew Huberman discusses TB-500 (as thymosin beta 4) among the tissue-repair peptides in Benefits & Risks of Peptide Therapeutics for Physical & Mental Health, noting that reported benefits are largely anecdotal, and sorting peptide products into prescription, grey-market and black-market tiers with warnings about contamination in the last. In a surgical-recovery context, orthopedic surgeon Dr. Jason Snibbe discusses TB-500 alongside BPC-157 with Gary Brecka in Peptides for ACL Recovery, BPC-157 & TB-500, Robotic Surgery, & Prehab — where Snibbe argues outcomes depend heavily on tissue quality, nutrition and metabolic health.
Coverage is thinner than for BPC-157: across the library, TB-500 is usually discussed as BPC-157’s recovery partner rather than on its own, which is why this hub is shorter.
Regulatory status
TB-500 traveled with the same group of contested peptides chronicled on the BPC-157 hub: placed in FDA’s Category 2 in 2023, removed from Category 2 in April 2026 without becoming lawfully compoundable, and — per RFK Team Report’s peptide chronicle, as of October 18, 2026 — voted 8–6 by the Pharmacy Compounding Advisory Committee on July 23–24, 2026 to recommend for the 503A Bulks List. As of that date it is not FDA-approved and not lawfully compoundable under 503A. Full timeline: rfkteamreport.com/peptides.
Go deeper by teacher
Related compound hubs: BPC-157 · GLP-1 medications · GHK-Cu · All peptides
Topic routes
Use TB-500 & Thymosin Beta-4 from more than one angle.
A reader can start with the person, the resource, or the lesson depending on what they need today.